Soligenix COVID-19 Vaccine Boosts Neutralizing Activity Against Covid-19 Including Delta and Omicron Variants

Soligenix COVID-19 Vaccine Boosts Neutralizing Activity Against Covid-19 Including Delta and Omicron Variants

Neutralizing antibodies increased up to 27-fold within one week; up to 243-fold within three weeks

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, shared notable results from its recent booster vaccination study in the fight against the SARS-CoV-2 virus. 

The company’s CiVax™ booster vaccine enhanced neutralizing antibody responses against Covid-19—including both the Delta and Omicron variants—in non-human primates.

The company’s CiVax™ booster vaccine enhanced neutralizing antibody responses against Covid-19—including both the Delta and Omicron variants—in non-human primates.

  • The CiVax™ booster vaccine was given seven months after primary vaccination; neutralizing antibodies against Delta and original strain increased up to 27-fold within one week and up to 243-fold within three weeks. Omicron neutralizing antibody levels were undetectable prior to booster vaccination, and attained presumed protective levels within one week of vaccination.
  • Of particular note, the CiVax™ vaccine platform is stable at ambient temperatures, potentially removing the need for frozen storage and distribution. CiVax™ previously demonstrated robust immune response in mice.
  • These results are consistent with the broad-spectrum activity observed to date with CiVax™ on primary vaccination, as described in an ACS Infectious Diseases article.

The ultimate goal is to find a faster resolution to the global pandemic and curb further evolution of the virus that causes Covid-19. Further, a vaccine built on many years of proven vaccine technology may be good news to vaccine-hesitant populations. Rapid vaccine administration worldwide is necessary to curtail disease spread and slow or pre-empt evolution of mutations.

These most recent results are part of the ongoing collaboration with Dr. Axel Lehrer, Associate Professor at the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine and University of Hawaiʻi at Mānoa. CiVax™ development continues under a non-dilutive $1.5 million Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases awarded to Soligenix in December 2020.

Watch Soligenix CSO Dr. Oreola Donini discuss the key developments of the the CiVax™ program

https://youtu.be/6DpeNDC7Nm4

Disclaimer

This communication was produced by Investors Prism, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

About the Author

Soligenix COVID-19 Vaccine Boosts Neutralizing Activity Against Covid-19 Including Delta and Omicron Variants

Editor Investors Prism